CLL-442

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCLL-442
Drug Alias NameCLL-442
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors +[5] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2PI3-kinase class I +[5] 
Therapy Area/IndicationsCarcinoma, Squamous Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A
Related LinksN/A